NEW DELHI: Biocon Ltd’s biologics partner Mylan received a favourable ruling from the US Patent and Trademark Appeal Board (PTAB) in its dispute with Sanofi over four patents of their insulin injection pen.
Sanofi had challenged that Mylan’s device for insulin glargine product Semglee infringed the company’s patents for Lantus SoloSTAR.
The PTAB, however, found Sanofi’s claims unpatentable. Sanofi’s Lantus is a long-acting insulin used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes for the control of high blood sugar, and the company sells the product in vials under the brand Lantus and disposable injection pens under the brand Lantus SoloSTAR.